These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31342373)

  • 1. Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score.
    Van Zee KJ; Zabor EC; Di Donato R; Harmon B; Fox J; Morrow M; Cody HS; Fineberg SA
    Ann Surg Oncol; 2019 Oct; 26(10):3282-3288. PubMed ID: 31342373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.
    Paszat L; Sutradhar R; Zhou L; Nofech-Mozes S; Rakovitch E
    Clin Breast Cancer; 2019 Feb; 19(1):35-46. PubMed ID: 30190195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
    Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
    Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
    Alvarado M; Carter DL; Guenther JM; Hagans J; Lei RY; Leonard CE; Manders J; Sing AP; Broder MS; Cherepanov D; Chang E; Eagan M; Hsiao W; Schultz MJ
    J Surg Oncol; 2015 Jun; 111(8):935-40. PubMed ID: 26031501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for Asian women with ductal carcinoma in situ of the breast.
    Wang F; Li H; Tan PH; Chua ET; Yeo RM; Lim FL; Kim SW; Tan DY; Wong FY
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):684-91. PubMed ID: 25194727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.
    Rakovitch E; Gray R; Baehner FL; Sutradhar R; Crager M; Gu S; Nofech-Mozes S; Badve SS; Hanna W; Hughes LL; Wood WC; Davidson NE; Paszat L; Shak S; Sparano JA; Solin LJ
    Breast Cancer Res Treat; 2018 Jun; 169(2):359-369. PubMed ID: 29388015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision.
    Yi M; Meric-Bernstam F; Kuerer HM; Mittendorf EA; Bedrosian I; Lucci A; Hwang RF; Crow JR; Luo S; Hunt KK
    J Clin Oncol; 2012 Feb; 30(6):600-7. PubMed ID: 22253459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
    Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
    J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ.
    Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Baehner FL; Miller DP; Fong C; Gu S; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Slodkowska E; Anderson JM; Cherbavaz DB; Shak S; Paszat L
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 30053207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study.
    Collins LC; Achacoso N; Haque R; Nekhlyudov L; Quesenberry CP; Schnitt SJ; Habel LA; Fletcher SW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S502-8. PubMed ID: 26059650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
    Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
    Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
    Rakovitch E; Parpia S; Koch A; Grimard L; Soliman H; Stevens C; Perera F; Kong I; Senthelal S; Anthes M; Wiebe E; Cao J; Goldberg M; Smith S; Spadafora L; Whelan TJ
    Breast Cancer Res Treat; 2021 Jul; 188(1):133-139. PubMed ID: 33830392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
    Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
    J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02).
    Kim K; Jung SY; Shin KH; Kim JH; Han W; Lee HB; Huh SJ; Choi DH; Park W; Ahn SD; Kim SS; Kim JH; Suh CO; Kim YB; Kim IA; Kim S; Kim YJ
    Breast Cancer Res Treat; 2017 Feb; 162(1):77-83. PubMed ID: 28083820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay.
    Lei RY; Carter DL; Antell AG; Nowels MA; Tole SP; Bennett JP; Turner M; Baehner FL; Leonard CE
    Adv Radiat Oncol; 2021; 6(2):100607. PubMed ID: 33912731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
    Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
    BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipsilateral tumor recurrence risk in women with ductal carcinoma in situ: application of the Van Nuys Prognostic Index and the Memorial Sloan Kettering Cancer Center nomogram.
    Hashiba KA; Bahl M
    Breast Cancer Res Treat; 2023 Nov; 202(1):185-190. PubMed ID: 37518825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram for predicting the risk of locoregional recurrence in patients treated with accelerated partial-breast irradiation.
    Wobb JL; Chen PY; Shah C; Moran MS; Shaitelman SF; Vicini FA; Mbah AK; Lyden M; Beitsch P
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):312-8. PubMed ID: 25446607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ.
    Rudloff U; Jacks LM; Goldberg JI; Wynveen CA; Brogi E; Patil S; Van Zee KJ
    J Clin Oncol; 2010 Aug; 28(23):3762-9. PubMed ID: 20625132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.